|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1997
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:atccode
|
A08 AA10
|
|
gptkbp:casnumber
|
84485-00-7
|
|
gptkbp:chemical_formula
|
C17 H26 Cl N
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
gptkb:Cardiology
gptkb:anorexia_nervosa
gptkb:bulimia_nervosa
hyperthyroidism
|
|
gptkbp:developed_by
|
gptkb:Abbott_Laboratories
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sibutramine hydrochloride
|
|
gptkbp:interacts_with
|
gptkb:beer
SSRIs
MAO inhibitors
tricyclic antidepressants
|
|
gptkbp:lifespan
|
14 hours
|
|
gptkbp:market_position
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:marketed_as
|
gptkb:Reductil
gptkb:Meridia
|
|
gptkbp:mechanism_of_action
|
gptkb:depression
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
gptkb:binge_eating_disorder
gptkb:guidelines
health risks
patient education
hypertension
metabolic syndrome
weight management
diabetes management
dietary changes
exercise programs
lifestyle modification
weight loss medications
obesity treatment
chronic weight management
serotonin syndrome
long-term weight loss
appetite suppressant
healthcare provider consultation
|
|
gptkbp:side_effect
|
insomnia
constipation
dry mouth
increased heart rate
|
|
gptkbp:used_for
|
weight loss
|
|
gptkbp:withdrawn_year
|
gptkb:2010
|
|
gptkbp:bfsParent
|
gptkb:Meridia
|
|
gptkbp:bfsLayer
|
5
|